...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada.
Reply New Message
Prev Message Back To Forum Threaded View Next Message

If that's case i wonder why we have yet to hear any large deal with Zenith.....

It's a possibility.  We just have to wait it out. 

Zenith is currently in an ongoing Phase 2 with ZEN-3694.  From the latest MD&A....

"On June 4, 2018,we announced that we had initiated the Phase 2 portion of the ongoing mCRPC clinical trial in patients that have progressed on an androgen receptor antagonist (“ARi").In Phase 2, weare focused on continuing the evaluation of efficacy and safety of ZEN-3694 in combination with enzalutamide (Xtandi)...."

 

5 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply